Non Small Cell Lung Cancer Clinical Trial
Official title:
A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients
100 suitable patients of lung cancer shall be taken into the study over a period of 2 years.
As per the existing treatment protocol in our department, all patients suitable shall undergo
a routine Pulmonary function testing (PFT). Subsequently, recording of the breath hold shall
be done at the following times
1. At time of simulation
2. At the time of first fraction of radiotherapy
3. At mid radiotherapy
4. At radiotherapy conclusion After the recording at a), patients shall be asked to perform
deep breathing exercises/spirometer ball exercise to see the effect of training on the
breath holding times.
100 suitable patients of lung cancer shall be taken into the study over a period of 2 years.
As per the existing treatment protocol in our department, all patients suitable shall undergo
a routine Pulmonary function testing (PFT). Subsequently, recording of the breath hold shall
be done at the following times
1. At time of simulation
2. At the time of first fraction of radiotherapy
3. At mid radiotherapy
4. At radiotherapy conclusion After the recording at a), patients shall be asked to perform
deep breathing exercises/spirometer ball exercise to see the effect of training on the
breath holding times.
Respiratory training All patients shall be sent for respiratory training to the physiotherapy
department. Patients shall be counseled about respiratory training by trained staff in their
own vernacular. Whenever possible, patients shall be provided one "Spiroball" device and
taught how to use the device. In addition/alternatively patients will be taught to do breath
exercises. Patients provided with spiroball shall be instructed to use the spiroball by the
prescribed technique. The following visit schedule shall be observed
1. st visit Within one day of the date of simulation
2. nd visit Date of Radiotherapy starting Subsequently 2 visits per week during
radiotherapy course shall be conducted (Tuesdays, Thursdays) During all the above visits
, respiratory training shall be reinforced and objective recording of the spirometer
ball(whenever used) shall be recorded.(Inspiratory volume)
The breathing exercises shall continue through radiotherapy. At all the above times,
recording shall be made of the breath holding times. In general at the start of each
recording a nasal clip shall be placed and the patient shall be asked to close the mouth
voluntarily. The closure of the mouth shall be done after nasal clip placement and then
stopwatch for recording shall be started. The end time shall be the moment when the patient
opens his mouth and starts breathing again. A one minute pause shall be kept between separate
recordings.
1. Deep inspiratory breath hold(DIBH): A clip shall be placed on the nose. The patient
shall be asked to take a deep breath from his mouth and then hold his breath.
2. Deep expiratory breath hold(DEBH): A clip shall be placed on the nose. The patient shall
be asked to exhale maximally from the mouth and then hold his breath.
3. Normal mid ventilation breath hold(NVBH): A clip shall be placed on the nose. The
patient shall be asked to hold breath in the middle of normal respiration.
Beam on/off times As mentioned before, all the patients shall be treated as per existing
departmental protocol. However, as a planning component of the study, after the patients have
been planned as per the routine protocol, the breath hold data in each phase shall be used to
calculate the number of times the radiation beam would have to be needed if patients were
treated with the above breath hold timings.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |